BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bor R, Fábián A, Matuz M, Szepes Z, Farkas K, Miheller P, Szamosi T, Vincze Á, Rutka M, Szántó K, Bálint A, Nagy F, Milassin Á, Tóth T, Zsigmond F, Bajor J, Müllner K, Lakner L, Papp M, Salamon Á, Horváth G, Sarang K, Schäfer E, Sarlós P, Palatka K, Molnár T. Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease – A nationwide Hungarian cohort study. Expert Opinion on Biological Therapy 2020;20:205-13. [DOI: 10.1080/14712598.2020.1699529] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Kim J, Yoon H, Kim N, Lee KM, Jung SA, Choi CH, Kim ES, Jung Y, Eun CS, Kim TO, Kang SB, Kim YS, Seo GS, Lee CK, Im JP, Park SJ, Park DI, Ye BD. Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study. Inflamm Bowel Dis 2021:izaa361. [PMID: 33501935 DOI: 10.1093/ibd/izaa361] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Fang S, Song Y, Zhang C, Wang L. Efficacy and safety of vedolizumab for pediatrics with inflammatory bowel disease: a systematic review. BMC Pediatr 2022;22:175. [PMID: 35379216 DOI: 10.1186/s12887-022-03229-x] [Reference Citation Analysis]
3 Oftedal BE, Wolff ASB. New era of therapy for endocrine autoimmune disorders. Scand J Immunol 2020;92:e12961. [PMID: 32853446 DOI: 10.1111/sji.12961] [Reference Citation Analysis]